In this webinar, Edward LeCluyse, PhD, Chief Scientist for LifeNet Health LifeSciences, will share the latest insights for how TruVivo can serve as a promising new tool for toxicity testing. 

Key learnings will be:

• How CYP and UGT enzymatic activity and transporter uptake in TruVivo remains functional and stable for greater than 14 days.
• How TruVivo accurately ranks the toxicity of several reference compounds representing multiple mechanisms of action.
• How the addition of human Kupffer cells in the TruVivo system successfully captures inflammatory and fibrogenic responses that lead to enhanced compound toxicity.